Stockscreener 앱 받기
9.79
3.71%
0.35
Satellos Bioscience Inc 주식(MSLE)의 최신 뉴스
Satellos Bioscience Inc.Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView
Satellos Bioscience Delivers Promising DMD Data With Fast Track Win - Streetwise Reports
Why Satellos Bioscience Inc. stock is skyrocketing today - Wealth Awesome
H.C. Wainwright Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data By Investing.com - Investing.com India
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data - Investing.com South Africa
Satellos reports six-month Phase II data for SAT-3247 in Duchenne muscular dystrophy - The Pharma Letter
HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock - MarketBeat
MSLE Maintained by HC Wainwright & Co. -- Price Target Raised to $18.00 - GuruFocus
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 - Investing News Network
Phase II DMD Trailhead data hike Satellos’ stock - BioWorld News
Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD - Moomoo
Satellos reports positive TRAILHEAD data for DMD drug - grafa.com
Why Is Satellos Bioscience Trading Higher Today?Satellos Bioscience (NASDAQ:MSLE) - Benzinga
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients - TipRanks
[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer) | MSLE SEC FilingForm 6-K - Stock Titan
Satellos Reports Six-Month Interim TRAILHEAD Data Showing - GlobeNewswire
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Sahm
Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
If You Invested $1,000 in Satellos Bioscience Inc (MSCLF) - Stock Titan
Why Satellos Bioscience Inc. stock is rising today - Wealth Awesome
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market - Streetwise Reports
Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome
Satellos Bioscience Ord Shs (MSLE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Guggenheim Maintains Satellos Bioscience(MSLE.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Satellos gets FDA Fast Track for SAT-3247 - grafa.com
Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation - marketscreener.com
Stocks in play: Satellos Bioscience Inc. - The Globe and Mail
Satellos Bioscience Shares Climb After FDA Fast Track Designation - Moomoo
Fast Track Designation for Satellos' SAT-3247 (MSLE) in Duchenne Treatment - GuruFocus
Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247 - TipRanks
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy - The Manila Times
FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program - Stock Titan
Satellos wins FDA Fast Track for Duchenne drug SAT-3247 - Stock Titan
Price to sales forward of Satellos Bioscience Inc – TSX:MSCL - TradingView
Satellos Bioscience Inc Actuals & Estimates (DUS:0IT) - TradingView
Price to earnings forward of Satellos Bioscience Inc – TSX:MSCL - TradingView
EBITDA margin % of Satellos Bioscience Inc – DUS:0IT - TradingView
Price to earnings forward of Satellos Bioscience Inc – DUS:0IT - TradingView
Enterprise value to revenue forward of Satellos Bioscience Inc – DUS:0IT - TradingView
Operating margin % of Satellos Bioscience Inc – DUS:0IT - TradingView
Satellos Bioscience Inc Statistics – DUS:0IT - TradingView
0IT Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Price to book forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Price to earnings forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Enterprise value to EBIT forward of Satellos Bioscience Inc – FWB:0IT - TradingView
Satellos Bioscience Inc Actuals & Estimates (TSX:MSCL) - TradingView
Satellos Bioscience Inc Actuals & Estimates (FWB:0IT) - TradingView
Satellos to Present Clinical Program Updates at ICNMD 2026 - Investing News Network
MSCL Forecast — Price Target — Prediction for 2027 - TradingView
Satellos to Present SAT-3247 Clinical Updates at ICNMD 2026 - TipRanks
Satellos (NASDAQ: MSLE) to present new SAT-3247 Duchenne data at ICNMD 2026 - Stock Titan
MSLE Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplinePreliminary Results - dars.gov.et
Satellos Bioscience Ord Shs (MSLE) Institutional Confidence - TradingKey
Why Satellos Bioscience Inc. stock is tanking today - Wealth Awesome
2.64%
자본화:
|
볼륨(24시간):